Adam B. Weiner

Oct 22, 2024 | urotoday.com | Adam B. Weiner

Read the Full Video TranscriptRuchika Talwar: Hi everyone. Welcome back to UroToday's Health Policy Center of Excellence. As always, my name is Ruchika Talwar, and I'm a urologic oncologist in Nashville, Tennessee. Today I'm so excited to be joined by my good friend Dr. Adam Weiner, who is a urologic oncologist at Cedars-Sinai Medical Center. He's here with us today discussing some important work he recently published on international variations in adherence to quality metrics for prostate cancer.

Jul 1, 2024 | targetedonc.com | Jordyn Sava |Adam B. Weiner

Adam Weiner, MD, a urologic oncology fellow at the University of California, Los Angeles, discusses his journey toward becoming an oncologist, highlighting his passion for personalized medicine in prostate cancer. He starts by discussing what drew him to the field and explains some of the key experiences he has gained thus far. Weiner emphasizes the importance of understanding one's passions and motivations.

May 22, 2024 | europeanurology.com | Adam B. Weiner |Andrew Armstrong |Alberto Bossi |La Garenne Colombes |Philip Cornford |Felix Feng | +9 more

Abstract Biochemical recurrence (BCR) after primary definitive treatment for prostate cancer (PCa) is a heterogeneous disease state. While BCR is associated with worse oncologic outcomes, risk factors that impact outcomes can vary significantly, necessitating avenues for risk stratification. We sought to identify prognostic risk factors at the time of recurrence after primary radical prostatectomy or radiotherapy, and prior to salvage treatment(s), associated with adverse oncologic outcomes.